María Queralt Salas
YOU?
Author Swipe
View article: Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation
Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation Open
Background: Post-transplant cyclophosphamide (PTCy) is a standard graft-versus-host disease (GVHD) prophylaxis in allogeneic hematopoietic cell transplantation (allo-HCT). While effective, concerns remain about cyclophosphamide-related car…
View article: Supplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Figure 2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
Clones of the K562 tumor cell line with different CD229 expression gradient
View article: Supplementary Figure 9 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Figure 9 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
Quantification of tumor burden by bioluminescence imaging over time of tumor cell infusion and luminescence at week 7 of each group.
View article: Supplementary Figure 1 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Figure 1 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
BCMA and CD229 antigen expression on different target cell lines used in different experiments.
View article: Supplementary Figure 5 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Figure 5 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
Cytokine production (IFNγ and IL-2) of CAR T-cells in co-culture with K562 cell lines with different expression of CD229 antigen tumor cells at the 24-hr time point measured by ELISA.
View article: Supplementary Figure 11 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Figure 11 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
Measurement of the strength of interaction between monospecific and bispecific CAR T cells and MM.1S and MM.1S BCMA KO cells.
View article: Supplementary Figure 10 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Figure 10 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
Generation of a cell line with low BCMA expression (MM.1S BCMA dim) from MM1S BCMA KO cells with an incomplete KO
View article: Supplementary Table 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Table 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
Experiments Raw Data
View article: Supplementary Figure 4 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Figure 4 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
Specific cytolytic activity of CAR T cells co-culture during 24h with K562 cell lines with different expression of CD229 antigen
View article: Data from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Data from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
Anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy has revolutionized the prognosis of patients with relapsed/refractory multiple myeloma. Regrettably, despite unprecedented overall response rates achieved…
View article: Supplementary Figure 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Figure 3 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
CAR T-cell proliferation when co-cultured for 72 hours with K562 cell lines with different expression of CD229 antigen
View article: Supplementary Figure 7 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Figure 7 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
Expansion of MM.1S and MM.1S BCMA KO cells during one week of culture.
View article: Supplementary Figure 12 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Figure 12 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
Percentage of PBMCs marked with FAR-RED Cell Trace dead after 24h of co-incubation with respective CAR T cells on a 1:1 ratio, normalized against dead cells from untransduced
View article: Supplementary Tables 1-2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Tables 1-2 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
scFv Sequences and antibody panels
View article: Supplementary Figure 6 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Figure 6 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
BCMA and CD229 antigen expression on wild-type and BCMA knock-out tumor cells.
View article: Supplementary Figure 8 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited
Supplementary Figure 8 from Bicistronic CAR T Cell against BCMA and CD229 Effectively Controls Myeloma Even When BCMA Expression Is Limited Open
Kaplan-Meier survival curve with a mixed group infused with 50% CD229-VLVH-BBζ + 50% ARI0002h
View article: HCT Frailty Scale (HCT-FS) for Assessing Frailty in Allogeneic Hematopoietic Cell Transplant Patients. Results from a Canadian and Spanish Initiative
HCT Frailty Scale (HCT-FS) for Assessing Frailty in Allogeneic Hematopoietic Cell Transplant Patients. Results from a Canadian and Spanish Initiative Open
INTRODUCTION: This collaborative study aims to present the results obtained from the implementation of the Hematopoietic Cell Transplantation Frailty Scale (HCT-FS) for the assessment of frailty in adult candidates for allogeneic hematopoi…
View article: Donor Age ≥30 Years as an Independent Predictor of Inferior Outcomes After Haploidentical Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Study Conducted on Behalf of GETH-TC
Donor Age ≥30 Years as an Independent Predictor of Inferior Outcomes After Haploidentical Hematopoietic Cell Transplantation in Acute Myeloid Leukemia. Study Conducted on Behalf of GETH-TC Open
This study evaluated the impact of donor age on clinical outcomes in 274 patients with acute myeloid leukemia (AML) haplo-HCT using PTCY-based prophylaxis. Median patient age was 53 years, with 42.6% classified as high-risk AML. The median…
View article: Current epidemiology of microbiologically documented infections and risk factors for multidrug resistance in hematologic patients presenting to the emergency department with suspected bacteremia
Current epidemiology of microbiologically documented infections and risk factors for multidrug resistance in hematologic patients presenting to the emergency department with suspected bacteremia Open
Objetivos. Describir los aislamientos microbiológicos obtenidos en pacientes hematológicos atendidos en urgencias a los que se les solicita hemocultivos e identificar los factores de riesgo de aislamiento de bacteria multirresistente (BMR)…
View article: Early cardiac events after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. subanalysis exploring cardiac toxicity conducted on behalf of GETH-TC
Early cardiac events after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide. subanalysis exploring cardiac toxicity conducted on behalf of GETH-TC Open
Introduction Haploidentical allogeneic hematopoietic cell transplantation (haplo-HCT) using post-transplant cyclophosphamide (PTCY) has become a standard approach for patients lacking HLA-matched donors. While effective in reducing graft-v…
View article: Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study
Hypomethylating agents plus venetoclax for high-risk MDS and CMML as bridge therapy to transplant: a GESMD study Open
Background High-risk myelodysplastic syndromes (HR-MDS) and chronic myelomonocytic leukemia (CMML) remain therapeutic challenges with suboptimal outcomes. The only potentially curative treatment is allogeneic stem cell transplantation (all…
View article: Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on Infectious Complications and Immune Reconstitution According to Donor Type
Post-Transplant Cyclophosphamide-Based Prophylaxis and Its Impact on Infectious Complications and Immune Reconstitution According to Donor Type Open
Background/Objectives: This study evaluated infectious complications and immune reconstitution in 253 adults undergoing peripheral blood allogeneic hematopoietic cell transplantation (allo-HCT) with post-transplant cyclophosphamide (PTCY)-…
View article: Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC) Open
View article: Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care
Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care Open
Introduction This multicenter prospective study sponsored by the Grupo Español de Transplante Hematopoyético y Terapia Celular (GETH-TC) explores the use of frailty assessments in allo-HCT candidates. Methods Frailty was measured using the…
View article: HCT Frailty Scale (HCT-FS) for Assessing Frailty in Allogeneic Hematopoietic Cell Transplant Patients. Results from a Canadian and Spanish Initiative
HCT Frailty Scale (HCT-FS) for Assessing Frailty in Allogeneic Hematopoietic Cell Transplant Patients. Results from a Canadian and Spanish Initiative Open
View article: At-Home Autologous Hematopoietic Cell Transplant for Adults with Hematological Malignancies. How Frailty Impacts and Evolves During Hct Procedure
At-Home Autologous Hematopoietic Cell Transplant for Adults with Hematological Malignancies. How Frailty Impacts and Evolves During Hct Procedure Open
View article: At-home autologous hematopoietic cell transplant for adults with hematological malignancies. How frailty impacts and evolves during HCT procedure. An observational, longitudinal, and prospective study
At-home autologous hematopoietic cell transplant for adults with hematological malignancies. How frailty impacts and evolves during HCT procedure. An observational, longitudinal, and prospective study Open
There was no association between the duration of at-home transplant hospitalisation and readmissions and the presence of frailty syndrome. Moreover, no patient died due to transplant-related toxicity. The results presented in this study su…
View article: Determinación de la sensibilidad antimicrobiana en aislamientos de enterobacterales aislados de aguas residuales y ríos con alto impacto antropogénico en Bogotá y municipios aledaños del departamento de Cundinamarca (Colombia)
Determinación de la sensibilidad antimicrobiana en aislamientos de enterobacterales aislados de aguas residuales y ríos con alto impacto antropogénico en Bogotá y municipios aledaños del departamento de Cundinamarca (Colombia) Open
View article: HCT Frailty Scale (HCT-FS) for Assessing Frailty in Allogeneic Hematopoietic Cell Transplant Patients. Results from a Canadian and Spanish Initiative
HCT Frailty Scale (HCT-FS) for Assessing Frailty in Allogeneic Hematopoietic Cell Transplant Patients. Results from a Canadian and Spanish Initiative Open
View article: Cardiac events after allo-HCT in patients with acute myeloid leukemia
Cardiac events after allo-HCT in patients with acute myeloid leukemia Open
This multicenter study sponsored by the GETH-TC investigates the incidence and predictors of early (first 100 days) and late cardiac events (CEs; ECEs and LCEs, respectively) after allo-HCT in patients with acute myeloid leukemia (AML) tre…